Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MYFED vs ADVIL CONGESTION RELIEF
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
ibuprofen: non-selective COX-1/COX-2 inhibitor reducing prostaglandin synthesis; phenylephrine: alpha-1 adrenergic receptor agonist causing vasoconstriction
Temporary relief of nasal congestion due to common cold, hay fever, or other upper respiratory allergies,Off-label: used as a stimulant or for weight loss (not recommended)
temporary relief of nasal congestion,sinus pressure,headache,fever,minor aches and pains associated with common cold or flu
500 mg orally twice daily with meals.
1 tablet (ibuprofen 200 mg / phenylephrine 10 mg) orally every 4 hours while symptoms persist, not to exceed 6 tablets in 24 hours.
3-5 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (Cr Cl <30 m L/min).
Ibuprofen: 2-4 hours (short half-life requires frequent dosing). Pseudoephedrine: 5-8 hours (longer in alkaline urine). Context: Half-life prolonged in renal impairment.
Hepatic metabolism via N-demethylation to active metabolite; undergoes some phase I and phase II metabolism; excreted renally.
ibuprofen: primarily hepatic via CYP2C9; phenylephrine: primarily hepatic via monoamine oxidase (MAO) and sulfation
Primarily renal (85-90% as unchanged drug) via glomerular filtration and tubular secretion; minor biliary/fecal excretion (5-10%).
Renal: ~90% as unchanged drug and metabolites (ibuprofen: <10% unchanged, pseudoephedrine: 43-96% unchanged). Biliary/fecal: minimal (<5%).
25-30% bound to serum albumin.
Ibuprofen: >99% bound to albumin. Pseudoephedrine: 20-30% bound to albumin.
1-2 L/kg, indicating extensive tissue distribution.
Ibuprofen: 0.1-0.2 L/kg (low, reflects high protein binding). Pseudoephedrine: 2.6-3.5 L/kg (extensive tissue distribution).
Oral: 60-70% due to first-pass metabolism.
Oral: Ibuprofen ~80-100% (high), Pseudoephedrine ~100% (high).
GFR ≥60 m L/min: 500 mg twice daily. GFR 30-59: 500 mg once daily. GFR <30: 500 mg every other day.
Avoid use if Cr Cl <30 m L/min. For Cr Cl 30-59 m L/min, use lowest effective dose and shortest duration.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 25%. Child-Pugh C: reduce dose by 50%.
Avoid use in severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh class B), use with caution and at the lowest effective dose.
Not recommended for pediatric use; safety and efficacy not established.
Not recommended in children under 12 years of age due to phenylephrine component. For children 12 years and older, same as adult dosing.
No specific dose adjustment required, but monitor renal function and adjust accordingly per renal adjustment guidelines.
Start at the low end of dosing range; avoid use in patients 65 years and older if possible due to increased risk of adverse effects; if necessary, use lowest effective dose for shortest duration.
None
ibuprofen carries a black box warning for increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal, and for serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines
Use with caution in hypertension, coronary artery disease, hyperthyroidism, diabetes, prostatic hypertrophy, and glaucoma. Avoid in patients with severe or uncontrolled hypertension. Prolonged use may lead to rebound congestion.
cardiovascular risk,gastrointestinal risk,renal effects,avoid concomitant use of other NSAIDs,hypertension,hyperthyroidism,diabetes,heart disease,use with MAOIs may cause hypertensive crisis
Severe hypertension, severe coronary artery disease, concurrent use of MAO inhibitors, narrow-angle glaucoma, urinary retention, and hypersensitivity to pseudoephedrine.
hypersensitivity to ibuprofen, phenylephrine, or any component,history of asthma, urticaria, or allergic-type reactions to aspirin or other NSAIDs,perioperative pain in setting of coronary artery bypass graft (CABG) surgery,severe hypertension,severe coronary artery disease,use of MAOIs or within 14 days of stopping MAOIs
Avoid high-tyramine foods (aged cheese, cured meats, fermented products) as pseudoephedrine may cause hypertensive crisis with MAOIs; do not use MYFED if you have taken an MAOI in the last 14 days. Grapefruit and grapefruit juice may increase anticholinergic effects.
Avoid alcohol consumption due to increased risk of GI bleeding and liver damage. No specific food interactions; take with food or milk to reduce stomach upset. Caffeine may exacerbate pseudoephedrine's stimulant effects; limit caffeine intake.
Category C: First trimester risk of major malformations not clearly increased; second and third trimester use associated with fetal tachycardia, premature closure of ductus arteriosus, and oligohydramnios. Avoid in third trimester.
First trimester: Avoid due to potential increased risk of cardiac defects and gastroschisis from NSAIDs. Second trimester: Use with caution; ibuprofen may cause oligohydramnios and premature ductus arteriosus constriction. Third trimester: Contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment. Phenylephrine: Limited human data; animal studies show fetal abnormalities at high doses; avoid in first trimester due to potential vascular disruption.
Excreted in breast milk; M/P ratio not established. Potential for infant irritability and sleep disturbance. Use caution; manufacturers recommend avoiding during breastfeeding.
Ibuprofen: Excreted into breast milk in low amounts (M/P ratio ~0.07). Compatible with breastfeeding; minimal infant exposure. Phenylephrine: Not known if excreted in breast milk; M/P ratio unknown. Avoid due to potential for infant hypertension and irritability. Alternative decongestants preferred.
No standard dose adjustment recommended for pregnancy. Increased renal clearance and volume of distribution may reduce peak concentrations; however, no evidence-based dose change is indicated. Use lowest effective dose for shortest duration.
Pharmacokinetic changes in pregnancy: Increased volume of distribution and clearance for ibuprofen may require higher doses, but avoid due to fetal risks. No standard dose adjustment recommended; use lowest effective dose for shortest duration. Phenylephrine: No specific dosing adjustments in pregnancy; avoid use due to limited safety data.
MYFED is a combination of pseudoephedrine (decongestant) and triprolidine (antihistamine). Avoid in patients with severe hypertension, coronary artery disease, or narrow-angle glaucoma. Use caution in elderly due to anticholinergic effects (confusion, urinary retention). May cause CNS stimulation or sedation; assess patient's response before driving.
Advil Congestion Relief combines ibuprofen (NSAID) and pseudoephedrine (decongestant). Ibuprofen can cause nephrotoxicity; pseudoephedrine can elevate blood pressure and heart rate. Avoid in patients with uncontrolled hypertension, severe CAD, or MAOI use within 14 days. Use with caution in elderly due to increased risk of GI bleeding and CNS effects. Not recommended for children under 12 years.
Take MYFED exactly as directed; do not exceed recommended dose due to risk of serious side effects.,Do not use with other products containing pseudoephedrine or other decongestants.,Avoid alcohol and sedatives as they may increase drowsiness.,Do not drive or operate machinery until you know how MYFED affects you.,Stop use and consult doctor if you experience fast, irregular heartbeat, severe dizziness, or difficulty urinating.
Do not take more than directed; do not use with other products containing ibuprofen or other NSAIDs (e.g., naproxen, aspirin) due to increased risk of stomach bleeding.,Avoid alcohol while taking this medication to reduce the risk of stomach irritation and bleeding.,Pseudoephedrine may cause insomnia, nervousness, or dizziness; take the last dose at least 4-6 hours before bedtime.,Stop use and consult a doctor if symptoms persist after 5 days (fever >3 days), if new symptoms appear, or if you experience signs of stomach bleeding (black/bloody stools, vomit with blood/coffee-grounds).,Do not use if you have heart disease, high blood pressure, thyroid disease, diabetes, glaucoma, or difficulty urinating due to an enlarged prostate unless directed by a doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MYFED vs ADVIL CONGESTION RELIEF, answered by our medical review team.
MYFED is a Decongestant that works by Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.. ADVIL CONGESTION RELIEF is a NSAID/Decongestant Combination that works by ibuprofen: non-selective COX-1/COX-2 inhibitor reducing prostaglandin synthesis; phenylephrine: alpha-1 adrenergic receptor agonist causing vasoconstriction. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MYFED and ADVIL CONGESTION RELIEF depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MYFED is: 500 mg orally twice daily with meals.. The standard adult dose of ADVIL CONGESTION RELIEF is: 1 tablet (ibuprofen 200 mg / phenylephrine 10 mg) orally every 4 hours while symptoms persist, not to exceed 6 tablets in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MYFED and ADVIL CONGESTION RELIEF in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MYFED is classified as Category C. Category C: First trimester risk of major malformations not clearly increased; second and third trimester use associated with fetal tachycardia, premature closure of ductus arterio. ADVIL CONGESTION RELIEF is classified as Category C. First trimester: Avoid due to potential increased risk of cardiac defects and gastroschisis from NSAIDs. Second trimester: Use with caution; ibuprofen may cause oligohydramnios and. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.